Table 1 Overview of MDS-UPDRS Part III MMRM and TTE analyses from the PASADENA full Part 1 data snapshot

From: Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson’s disease trials

MDS-UPDRS Part III (“OFF” medication state) at baseline mITTa Placebo (n = 105) vs. prasinezumab pooledb (n = 211)

Estimand strategy

Hypothetical strategy

Treatment policy strategy

Least square mean ± SE from MMRM at Week 52 [80% CI]

Placebo (n = 76):

5.57 ± 0.897 [4.42, 6.72]

Prasinezumab pooled (n = 147):

4.12 ± 0.646 [3.29, 4.95]

Placebo (n = 105):

2.68 ± 0.841 [1.60, 3.76]

Prasinezumab pooled (n = 205):

1.95 ± 0.606 [1.17, 2.73]

Difference in least square mean [80% CI] at Week 52

−1.44 [ − 2.84, -0.05]

−0.73 [−2.04, 0.57]

Hazard ratio from TTE [80% CI] (using Cox proportional hazard model)

0.82 [0.68, 0.98]

(N = 316; 2:1 prasinezumab to placebo ratio)

0.84 [0.70, 1.00]

(N = 316; 2:1 prasinezumab to placebo ratio)

  1. amITT population enrolled in Part 1 of PASADENA.
  2. bPooled prasinezumab doses, either 1500 mg or 4500 mg, for 52 weeks.
  3. CI confidence interval, MDS-UPDRS Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale, mITT modified intent-to-treat, MMRM Mixed-effect Model for Repeated Measures, SE standard error, TTE time-to-event.
Back to article page